Steve Potts, PhD, MBA, CEO and Co-Founder, Stealth Cancer Biotech

from Perspectives by the Leerink Center for Pharmacoeconomics · host The Leerink Center for Pharmacoeconomics

Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics, interviews Steve Potts, PhD, MBA, CEO and Co-Founder, Stealth Cancer Biotech, to discuss the impact of the Inflation Reduction Act on cancer drug development and a middle ground between a market-based approach and a government-based approach to drug pricing.

Episode metadata supplied by the publisher feed · Published Oct 6, 2025

Embed this episode

Attribution link and audio player

Ready to play

Steve Potts, PhD, MBA, CEO and Co-Founder, Stealth Cancer Biotech

0:00 41:43

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Perspectives by the Leerink Center for Pharmacoeconomics?

This episode is 41 minutes long.

When was this Perspectives by the Leerink Center for Pharmacoeconomics episode published?

This episode was published on October 6, 2025.

Can I download this Perspectives by the Leerink Center for Pharmacoeconomics episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!